Search academic texts

Information × Registration Number 0226U000436, (0123U100390) , R & D reports Title To develop differentiated approaches to the treatment of patients with coronavirus-related lung damage at different stages of the disease popup.stage_title Розробити диференційовані заходи лікування хворих з ураженням легень коронавірусної етіології на різних етапах перебігу захворювання Head Dziublik Oleksandr Ya., д.мед.н. Registration Date 09-01-2026 Organization State organization "National scientific center of phthisiatry, pulmonology and allergology named after F. G. Yanovskyi National academy of medical sciences of Ukraine" popup.description1 To improve the treatment of patients with coronavirus-related lung damage by differentiated using of etiotropic and pathogenetic therapy at different stages of the disease popup.description2 The object of the study – patients with lesions of the lungs of coronavirus etiology; strains of viruses. The aim of the work is to improve the treatment of patients with lung lesions of coronavirus etiology by differentiated use of drugs with etiotropic and pathogenetic effect at different stages of the disease. Methods – clinical and radiological, microbiological, statistical. According to the developed microbiological research methodology, it was found that aminocaproic acid (ACC) in the model of infectious bronchitis coronavirus IBV in a sensitive cell culture under in vitro conditions effectively suppresses virus reproduction 24 and 48 hours after application in the range of non-toxic concentrations (ID50 within (7.91-15.82), which indicates the safety and antiviral activity of ACC in the early stages of coronavirus reproduction. Based on the data obtained, new methods of etiotropic (ET) and pathogenetic therapy (PT) for patients with a mild course of COVID-19 and the presence of risk factors for disease progression were developed and tested, which consist in the use of inhaled ACC in the first 5 days of the disease, as well as the simultaneous use of drugs with ET that affect different links in the pathogenesis of COVID-19, namely the inhaled corticosteroid budesonide, the antioxidant drug acetylcysteine, and the nitric oxide donor L-arginine aspartate. According to the created model for assessing the effectiveness, safety and cost-effectiveness of treatment, it was found that the new ET method allows achieving faster (by 2-3 days) clinical improvement and reducing the development of adverse events by 20.8%, which reduces the total cost of treatment for this category of patients, and the combination of ET with multitarget PT reduces the need for respiratory support and emergency care, prevents the development of complications and prolongation of the disease, reduces the total duration of hospitalization by 2.1 days. Sphere of application – pulmonology. Product Description popup.authors Gumenuk Mykola I Svitlana A. Bychkova Denysova Olha V. Vitalii A. Yachnyk Yakovenko Oleh K. Дзюблик Олександр Ярославович Rostyslav Y. Sukhin Diachenko Viktor V. Kapitan Heorhii B. Serhii Soloviov TTrokhymenko Olena P. Iryna V. Dziublyk Velychko Olha O. Olena Bororova Natalia V. Surtaeva Mykhailo P. Smetyukh Dmytro S. Gorodetsky popup.nrat_date 2026-01-09 Close